The FDA has granted rolling review for Palvella Therapeutics' New Drug Application (NDA) for QTORIN™ rapamycin, aimed at treating microcystic lymphatic malformations (LMs), a rare and serious disease with no approved therapies. This expedited review allows the FDA to evaluate sections of the application as they are completed, speeding up the approval process. Palvella plans to submit the full NDA in the second half of 2026 and aims for QTORIN™ rapamycin to become the first FDA-approved treatment for over 30,000 U.S. patients affected by this chronic condition. The drug targets the disease mechanism locally to minimize side effects, offering hope for a condition that currently has limited treatment options.
Christopher Derrick, known for writing on Star Trek: Picard and The Equalizer, premieres his first film as sole writer-director, Moral Dirt, at the Academy Award® Qualifying LA Shorts International Film Festival on August 3, 2026. The 15-minute psych...
Arcutis Biotherapeutics has appointed Chris Peetz to its Board of Directors as of July 15, 2026. Peetz brings extensive experience leading biopharmaceutical companies through growth phases, product development, and strategic acquisitions. His additio...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
